SRC and glioblastoma: Compound 30 (Figure 7) showed a promising inhibitory activity against Src (Ki = 3.14 μM) and Abl (Ki = 0.44 μM) kinases, cell viability reduction towards U-87, LN-18, LN-229 and DBTRG GBM cell lines.